| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$87.5M | ROE | −55.00% |
| Net Margin | — | ROIC | −96.44% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on hereditary and acquired diseases with high unmet need in the United States. Its pipeline includes LX2006, an AAVrh10-based gene therapy in phase 1/2 trials for Friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based candidate in phase 1/2 delivering a functional PKP2 gene for PKP2-ACM; and the preclinical LX2021 targeting connexin 43 for inherited cardiac muscle disorders. The company is also developing LX2022.
| Market Cap | $344.7M | Trading Days | 677 |
| 52W High | 10.99 |
| 52W Low | 3.91 |
| % Off High | −60.05% |
| YTD | −55.79% | 1Y | 3.05% |
| Since incept. (ann.) | −26.15% |
| Ann. Volatility (1Y) | 78.03% | Ann. Volatility (3Y) | 99.97% |
| Sharpe (1Y) | 0.42 | Sharpe (3Y) | 0.18 |
| Max Drawdown (1Y) | −60.49% | Max Drawdown (3Y) | −90.46% |
| Beta (3Y, vs SPY) | 1.44 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | $345.3M | — |
| PALI | PALISADE BIO, INC. | $350.6M | — |
| CMPX | Compass Therapeutics, Inc. | $367.4M | — |
| IPSC | Century Therapeutics, Inc. | $369.7M | — |
| XFOR | X4 Pharmaceuticals, Inc | $370.7M | — |
| AUTL | Autolus Therapeutics plc | $385.9M | — |
| NMRA | Neumora Therapeutics, Inc. | $307.6M | — |
| IKT | Inhibikase Therapeutics, Inc. | $305.0M | — |
| CCCC | C4 Therapeutics, Inc. | $392.5M | — |
| STRO | SUTRO BIOPHARMA, INC. | $393.2M | — |
| OCGN | Ocugen, Inc. |
| $419.8M |
| — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
